Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Provided By GlobeNewswire
Last update: Nov 7, 2024
– Interim data from ongoing Phase 1 clinical trial of WTX-330, further characterizing tolerability and activity profile, to be presented at SITC Annual Meeting –
Read more at globenewswire.com0.6868
+0.04 (+6.22%)
Find more stocks in the Stock Screener
HOWL Latest News and Analysis
